BPG is committed to discovery and dissemination of knowledge
Featured Articles
11/19/2020 3:26:25 AM | Browse: 93 | Download: 143
Publication Name World Journal of Clinical Oncology
Manuscript ID 55638
Country/Territory United Kingdom
2020-03-29 23:42
Peer-Review Started
2020-03-29 23:53
To Make the First Decision
Return for Revision
2020-06-20 21:56
2020-07-29 20:19
Second Decision
2020-11-04 09:48
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-11-05 19:32
Articles in Press
2020-11-05 19:32
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2020-11-16 13:02
Publish the Manuscript Online
2020-11-18 14:20
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Review
Article Title Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes
Manuscript Source Invited Manuscript
All Author List Laura Feeney, Ian JG Harley, W Glenn McCluggage, Paul B Mullan and James P Beirne
Funding Agency and Grant Number
Corresponding Author James P Beirne, MBChB, PhD, Doctor, Trinity St James Cancer Institute, St. James’ Hospital, James’ Street, Dublin 8, Ireland. j.beirne@qub.ac.uk
Key Words Epithelial ovarian cancer; Molecular profile; Liquid biopsy; Circulating tumor DNA; Biomarker discovery; Precision medicine
Core Tip Epithelial ovarian cancer (EOC), particularly high-grade serous carcinoma, is a gynaecological malignancy with a poor survival rate. Currently there is no effective disease-specific biomarker, which could improve detection rates and treatment algorithms, for any of the EOC types - this is an area of unmet clinical need. Circulating tumour DNA (ctDNA) analysis has emerged as a potential blood-based “liquid biopsy” for early detection, diagnosis, staging and prognosis, monitoring response to treatment, monitoring minimal residual disease and relapse and identifying acquired drug resistance mechanisms. However, there are several obstacles to the development of cfDNA-based biomarkers which are discussed further in this in-depth review.
Publish Date 2020-11-18 14:20
Citation Feeney L, Harley IJ, McCluggage WG, Mullan PB, Beirne JP. Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes. World J Clin Oncol 2020; 11(11): 868-889
URL https://www.wjgnet.com/2218-4333/full/v11/i11/868.htm
DOI https://dx.doi.org/10.5306/wjco.v11.i11.868
Full Article (PDF) WJCO-11-868.pdf
Full Article (Word) WJCO-11-868.docx
Manuscript File 55638_Auto_Edited.docx
Answering Reviewers 55638-Answering reviewers.pdf
Audio Core Tip 55638-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 55638-Conflict-of-interest statement.pdf
Copyright License Agreement 55638-Copyright license agreement.pdf
Peer-review Report 55638-Peer-review(s).pdf
Scientific Misconduct Check 55638-Bing-Yu XQ-1.png
Scientific Misconduct Check 55638-Scientific misconduct check.pdf
Scientific Editor Work List 55638-Scientific editor work list.pdf